AiViva’s Diverse Product Pipeline Could Have The Potential To Transform Unmet Medical Needs – Yahoo Finance

By Gita Karunakaran, Benzinga
Newport Beach, CA –News Direct– AiViva BioPharma
AiViva BioPharma is a clinical-stage biotech company developing innovative and transformative treatments and products to address unmet medical needs for a wide array of diseases.
AiViva has created a diverse product pipeline powered by its proprietary technology and new and innovative treatments. It has built a strong patent position to protect products to be commercialized for worldwide sales from its diverse product pipeline for ophthalmology, dermatology, urology, and oncology.
The company has a veteran management team with a combined 300 years of experience at its helm. The California-based company has raised $30+ million in capital, including $10 million in 2022, and is buzzing with action and optimism.
It boasts a robust clinical pipeline focused on wet, age-related macular degeneration (wAMD), prostate disorders, and nonmelanoma skin cancer.
AiViva’s proprietary JEL™ technology is aimed at prolonging the therapeutic effects of drugs and enhancing their benefits. A key outcome of this strategy is a reduction in treatment frequency and systemic toxicity, which relieves patients of multiple visits to the doctor while gaining improved outcomes.
AiViva’s JEL™ technology allows for the placement of the drug directly at the site of disease, where it forms a drug-infused mass or drug depot for prolonged drug release. Its delivery medium is a liquid at room temperature. When it’s injected into the diseased tissue at a warmer body temperature, it quickly hardens into a gelatin-like mass. This drug-infused gelatin serves as a storehouse, releasing the drug for release over time.
The company says its JEL™ delivery platform offers customizable drug release and treatment duration for different therapies, making it a versatile drug delivery platform for the treatment of many major diseases, including solid tumors and wAMD.
AiViva’s current focus is wAMD, and it’s set to begin clinical trials using its AIV007 compound combined with JEL™ in 2023.
wAMD is a chronic eye disorder that causes blurred vision or a blind spot caused by abnormal blood vessels that leak fluid or blood into the macula — the area of the eye that provides the sharp, central vision needed for reading, driving and seeing fine detail — and scars it over time.
Current treatments for this disorder only address the abnormal blood vessel growth (neovascularization) — not the formation of scar tissue or fibrosis. Leaving the scar tissue untreated could result in irreversible vision loss. There is no cure for wAMD.
AiViva says its novel compound AIV007 embedded in JEL™ offers superior outcomes for wAMD because it targets neovascularization and addresses cell proliferation and fibrosis (scarring), improving impaired vision or preventing vision loss.
In addition, AIV007 in JEL™ delivers localized and precise treatment, unlike most medicines that spread throughout the body randomly. AiViva’s technology only requires placing a tiny amount of drug at the disease site and ensures the drug remain there for a long treatment effect. This precision medicine would achieve good therapy outcome without annoying side effects, reduce the number of doctor’s visits.
Applying the principles of its JEL™ technology, AiViva is targeting other major diseases that involve neovascularization, abnormal tissue growth and fibrosis, including benign prostate hyperplasia (enlargement of men’s prostates), low-grade prostate cancers and skin disorders.
AiViva has ongoing clinical trials in skin cancer and keloid scarring for the compound AIV001. It has wAMD lined up as its next candidate for clinical trials.
The indications targeted by AiViva represent a combined multi billion revenue potential, according to the company. The technology is protected beyond 2040 by patent applications in major markets, including Europe, Japan, China and the U.S.
The company reports allocating almost 80% of its capital to research and development in the past years, through which it has been able to bring several projects through Food and Drug Administration’s (FDA) Investigational New Drug Applications (INDs).
AiViva’s website highlights a management team of highly experienced industry experts with successful track records in drug development and commercialization. Its board members have been described as having led successful initial public offerings (IPOs) on the New York Stock Exchange (NYSE) and the Nasdaq Stock exchange. Here’s a look at some of them:
Co-Founder and CEO Diane Tang-Liu held several senior executive positions at Allergan Plc. (NYSE: AGN), leading research and development (R&D) programs for over 30 years.
Director Johnson Lau is CEO of Athenex Inc. (NASDAQ: ATNX) and was chair of the $75 million Athenex IPO in 2017. Johnson was previously CEO of Ribapharm Inc. (NYSE: RNA), which launched a $299 million IPO on the New York Stock Exchange in 2002 — the second-largest biotech IPO in history at the time.
Director Larry Hsu was co-founder, president and CEO of Impax Laboratories Inc. (NASDAQ: IPXL), a company that had a market cap of about $3 billion at the time of his retirement.
Director Jinn Wu was Dr. Jinn Wu is the Founder and President of XenoBiotic Laboratories, Inc. (XBL) in Plainsboro, New Jersey, and XBL-China in Nanjing, China. WuXi PharmaTech (Cayman) Inc. (NYSE: WX), acquired XenoBiotic Laboratories, Inc.
With an impressive team leading the charge at AiViva, the company is optimistic about its ability to raise capital and believes its investors could reap high returns on their investment if the past experience of its collective leadership in leading IPOs is anything to go by.
To learn more about AiViva visit the company website.
To invest in AiViva go here.
AiViva is a clinical stage biotech company which has created proprietary technology and new treatments to address significant, unmet medical needs in ophthalmology, dermatology, urology, and oncology. The company is led by a team of seasoned industry experts who have an outstanding track record in successful drug development, commercialization, and multiple IPOs on the NYSE and NASDAQ.
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. Benzinga may receive monetary compensation from the issuer, or its agency, for publicizing the offering of the issuer’s securities. This content is for informational purposes only and is not intended to be investing advice. This is a paid ad. Please see 17(b) disclosure linked in the campaign page for more information.
[email protected]
View source version on
Gaithersburg’s NexImmune Inc., an 11-year-old biotech developing immunotherapy treatments for cancer and autoimmune diseases, is cutting clinical programs — and laying off the workers who run them. It makes NexImmune the latest among a growing group of biotech firms across the industry that have cut staff this year, some because of regulatory failures and clinical trial flops, and others due to broader economic challenges. The company did not say in its filings when the layoffs take effect, but a Worker Adjustment and Retraining Notification (WARN) filing with Maryland pegs the effective date as Jan. 16.
When was the right time to sell top stocks such as data specialist Splunk after its breakout in 2018? The chart action gave clues it wasn't acting right.
There’s one more thing you should avoid talking about during Thanksgiving dinners and other social events: how U.S. retailers are faring with their Thanksgiving weekend sales. More often than not, they lead you in the wrong direction. For example, if initial reports show retail sales are weaker than expected and the stock market falls, it more often than not will reverse itself and rise through the end of the year.
Carriage Services, Inc. ( NYSE:CSV ), is not the largest company out there, but it saw significant share price movement…
(Bloomberg) — Most Read from BloombergMalaysia Latest: Muhyiddin Turns Down King on Unity GovernmentSwedish Housing Is Now in the Worst Rout Since the 1990sCrypto Brokerage Genesis Is Said to Warn of Bankruptcy Without FundingBeyond Meat Plant’s Dirty Conditions Revealed in Photos, DocumentsDisney Shares Jump on Optimism Over Iger’s Surprise ReturnIn a year when most of the world’s stock markets are flagging, Turkey’s is an outlier.The country’s stock market has soared to a record high in 2022
While The Timken Company ( NYSE:TKR ) might not be the most widely known stock at the moment, it led the NYSE gainers…
While Cleveland Federal Reserve President Loretta Mester, a voting member of the rate-setting panel, supported a smaller rate hike in December, San Francisco Fed President Mary Daly stressed on Monday the need to be careful to avoid a "painful downturn". Traders widely expect the Fed to raise rates by 50 basis points in December, with some even betting on a 28.9% chance of a 75-bps hike, according to CME Group's FedWatch Tool. Although several policymakers have signaled a shift to smaller increases to allow the economy to absorb any monetary policy shocks, they have also underscored the need for a longer period of tightening to combat sticky inflation.
Is Merck stock a buy after the company announced its acquisition of Imago, a bone marrow diseases company? Is MRK stock a buy now?
(Bloomberg) — Hyperloop Transportation Technologies, a technology-licensing company, has agreed to merge with blank check firm Forest Road Acquisition Corp. II, according to a statement confirming an earlier report by Bloomberg News.Most Read from BloombergMalaysia Latest: Muhyiddin Turns Down King on Unity GovernmentSwedish Housing Is Now in the Worst Rout Since the 1990sCrypto Brokerage Genesis Is Said to Warn of Bankruptcy Without FundingBeyond Meat Plant’s Dirty Conditions Revealed in Photo
The pool of available value stocks dramatically increased over the last year. Many growth stocks have taken a big hit this year, changing the category they fall into. This could bode well for value stocks such as Alphabet (NASDAQ: GOOGL) (NASDAQ: GOOG), Qualcomm (NASDAQ: QCOM), and Target (NYSE: TGT).
The lender is reported to have been rebuffed in its attempts to raise investment following a flood of withdrawals.
(Bloomberg) — Best Buy Co. jumped after raising its profit forecast, surprising Wall Street with an upbeat earnings report even as US shoppers rein in spending on discretionary goods. Most Read from BloombergMalaysia Latest: Muhyiddin Turns Down King on Unity GovernmentSwedish Housing Is Now in the Worst Rout Since the 1990sCrypto Brokerage Genesis Is Said to Warn of Bankruptcy Without FundingBeyond Meat Plant’s Dirty Conditions Revealed in Photos, DocumentsDisney Shares Jump on Optimism Over I
Veru (NASDAQ: VERU), a biopharmaceutical company that looks for novel cancer therapies, particularly in breast cancer or prostate cancer, saw its shares drop 10.33% on Monday. The company's stock already lost $10 a share two weeks ago when a Food and Drug Administration (FDA) advisory panel voted 8-5 against approving sabizabulin, Veru's COVID-19 oral therapy, via the Emergency Use Authorization route. It's not the last word, but the FDA usually agrees with advisory panels' votes.
High Tide Inc. ("High Tide" or the "Company") (NASDAQ: HITI) (TSXV: HITI) (FSE: 2LYA), a leading retail-focused cannabis company with bricks-and-mortar as well as global e-commerce assets, announced today that according to new data recently released by the cannabis business publication, New Cannabis Ventures, the Company is now Canada's top revenue-generating cannabis company1.
For anyone looking to get ahead in the investing game, following in the footsteps of stock picking legends is an obvious path to follow. Hardly any are more legendary than George Soros, forever known as the ‘man who broke the Bank of England,’ after pocketing a cool billion dollars in one day when betting against the Pound back in 1992. That single act, however, does not define Soros, who has made sound investment decisions throughout his career which bought decades-long returns of 30% to his Qu
These supercharged income stocks, with yields ranging from 8.5% to 17.7%, were on billionaire money manager's buy lists during the third quarter.
Yahoo Finance Live anchor Dave Briggs looks at SoFi shares following a letter from the Senate's Banking Committee.
In this article, we talk about 10 stocks that billionaire Ray Dalio dumped from his portfolio. If you want to see more stocks in this selection, check out Billionaire Ray Dalio is Dumping These 5 Stocks. Ray Dalio is an American billionaire hedge fund manager, philanthropist, and the founder of Bridgewater Associates, one of the […]
Wharton Professor Jeremy Siegel says 90% of U.S. inflation is already gone, but Bill Ackman is warning investors not to forget about deglobalization.
With a price-to-earnings (or "P/E") ratio of 24.9x Blackstone Inc. ( NYSE:BX ) may be sending very bearish signals at…


Leave a Reply

Your email address will not be published.